Bristol goes pivotal with SystImmune-partnered conjugate
The first global phase 3 trial will be in first-line triple-negative breast cancer.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
